<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03108521</url>
  </required_header>
  <id_info>
    <org_study_id>2015SZ0182</org_study_id>
    <nct_id>NCT03108521</nct_id>
  </id_info>
  <brief_title>SNP Study of DPP-4 and GLP-1R in Chinese People (Including Diabetes Patients)</brief_title>
  <official_title>Study on Polymorphism of DPP-4 and GLP-1R Genes in Chinese Population and Its Empirical Study on Treatment of Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sichuan Provincial People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sichuan Provincial People's Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Incretin-based therapy is currently one of the most popular diabetes treatment approaches.&#xD;
      However, differences of response ware found in previous studies. We hypothesis that SNPs of&#xD;
      DPP-4, GLP-1 and GLP-1R genes may play crucial roles in the response differences. Therefore,&#xD;
      this study aims to investigate the correlation of incretin-related gene polymorphism and&#xD;
      individual differences in the response of DPP-4 inhibators (take Sitagliptin as an example).&#xD;
      In addition, The distribution differences of the SNPs in diabetics and non-diabetics are&#xD;
      evaluated to study the relationships between the SNPs and diabetes onsets.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Single Nucleotide Polymorphism (SNP) plays an important role in the differences of clinical&#xD;
      manifestations and drug responses of diseases. The vast majority of SNP sites are located in&#xD;
      the non-coding region of the gene (about 95%), which is called SNP(non-coding SNP (ncSNP),&#xD;
      while the other part of SNP is located in the coding region of the gene, which is called&#xD;
      coding SNP (cSNP). Furthermore, cSNP can be divided into two categories: SNP that does not&#xD;
      change the encoded amino acid sequence is called synonymous SNP(synonymous SNP, SSNP); SNP&#xD;
      that changes amino acid sequence is called SNP(non-synonymous SNP (NSNP). Although not&#xD;
      involved in coding amino acid, some ncSNPs may also affect the regulation of protein&#xD;
      expression. Therefore, it is of great significance to study the effects of NC SNP and cSNP on&#xD;
      the occurrence and development of diseases and drugs.&#xD;
&#xD;
      DPP-4 enzyme inhibitor is combined with DPP-4 enzyme in human body to reduce hydrolysis of&#xD;
      active GLP-1, thus increasing the level of endogenous active GLP-1. Active GLP-1 combines&#xD;
      with its receptor GLP-1R to promote insulin release and inhibit glucagon release in&#xD;
      hyperglycemia state, and produces opposite effect in hypoglycemia state.&#xD;
&#xD;
      Based on the above principles, we speculate that SNP of genes that may affect the&#xD;
      hypoglycemic effect of DPP-4 enzyme inhibitor are:&#xD;
&#xD;
        1. SNP of DPP-4 enzyme gene. SNP of DPP-4 enzyme gene may affect the enzyme activity and/or&#xD;
           protein expression level of DPP-4. Assuming that the effect of DPP-4 enzyme inhibitor is&#xD;
           sufficient, patients with higher DPP-4 enzyme activity are more sensitive to DPP-4&#xD;
           enzyme inhibitor drugs; However, for patients with low DPP-4 enzyme activity, DPP-4&#xD;
           enzyme inhibitor drugs cannot play a stronger role in lowering blood sugar.&#xD;
&#xD;
        2. SNP of GLP-1 gene. SNP of GLP-1 gene may affect activity or expression level of GLP-1.&#xD;
           Patients with high GLP-1 level are more sensitive to DPP-4 enzyme inhibitor drugs.&#xD;
&#xD;
        3. SNP of GLP-1R gene. SNP of GLP-1R gene may affect activity or expression level of&#xD;
           GLP-1R. Patients with high GLP-1R level are also more susceptible to DPP-4 enzyme&#xD;
           inhibitor drugs.&#xD;
&#xD;
      However, studies on the hypoglycemic effect of DPP-4, GLP-1 and their receptors on DPP-4&#xD;
      enzyme inhibitors in the treatment of T2DM are rare, which is not conducive to the evaluation&#xD;
      of individualized treatment of such drugs. Therefore, this chapter intends to select SNP&#xD;
      sites with high mutation frequencies of DPP-4, GLP-1 and GLP-1R genes to study the mutation&#xD;
      frequencies of these SNPs in diabetic patients and non-diabetic patients and their effects on&#xD;
      DPP-4 enzyme inhibitor sitagliptin's hypoglycemic effect on T2DM patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 21, 2016</start_date>
  <completion_date type="Actual">October 8, 2018</completion_date>
  <primary_completion_date type="Actual">January 4, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycosylated Hemoglobin A1c (HbA1c)</measure>
    <time_frame>12 weeks later</time_frame>
    <description>non-T2D subjects only tested HbA1c at baseline. Of the 71 patients who completed the study, 69 collected HbA1c at both baseline and study endpoint, and 2 subjects did not carry out HbA1c measurement for personal reasons.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Types of Gene Polymorphism</measure>
    <time_frame>Baseline</time_frame>
    <description>24 SNPs genetic points of DPP-4, GLP-1 and GLP-1R.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Blood Glucose</measure>
    <time_frame>Basline and 12 weeks later. Fasting, 0.5h, 2h,3h after take 75g glucose orally.</time_frame>
    <description>Fasting Blood glucose, the postprandial 0.5-hour,2-hour,3-hour blood glucose were measured at baseline and at study end points, and the difference between baseline and study end points were compared.Participants in &quot;Non-T2DM Group&quot; were not taking Sitagliptin, so their blood glucose were not measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Insulin</measure>
    <time_frame>Basline and 12 weeks later. Fasting and 0.5h, 2h,3h after take 75g glucose orally.</time_frame>
    <description>Fasting insulin, the postprandial 0.5-hour,2-hour,3-hour insulin were measured at baseline and at study end points, and the difference between baseline and study end points were compared.The changes in fasting insulin, the postprandial 0.5-hour,2-hour,3-hour insulin were compared among patients with different genotypes at baseline and at study end points.Participants in &quot;Non-T2DM Group&quot; were not taking Sitagliptin, so their insulin were not measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in C-peptide</measure>
    <time_frame>Basline and 12 weeks later. Fasting and 2h after take 75g glucose orally.</time_frame>
    <description>Fasting C-peptide, the postprandial 2-hour C-peptide were measured at baseline and at study end points, and the difference between baseline and study end points were compared.The changes in fasting C-peptide, the postprandial 2-hour C-peptide were compared among patients with different genotypes at baseline and at study end points.Participants in &quot;Non-T2DM Group&quot; were not taking Sitagliptin, so their C-peptide were not measured.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">119</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Sitagliptin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients in this group will accept Sitagliptin phosphate tablets as their intervention. Specifications: Each tablet 100mg (with sitagliptin dollars). Regimen: The recommended dose is 100mg.QD for 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>non-T2DM group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subjects in this group are T2D free. We use their gene information to study SNP differences between T2D patients and non-T2DM people.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sitagliptin</intervention_name>
    <description>100mg.QD for 3 months</description>
    <arm_group_label>Sitagliptin group</arm_group_label>
    <other_name>Januvia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For Sitagliptin group--&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. According to diagnostic criteria from Chinese type 2 diabetes prevention and treatment&#xD;
             guidelines in diabetes, that published in the Chinese Medical Association Diabetes&#xD;
             credits in 2010: Symptoms of diabetes (polydipsia, polyphagia, polyuria, weight loss,&#xD;
             itchy skin, blurred vision and other acute metabolic disorders performance caused by&#xD;
             hyperglycemia) and RBGâ‰¥11.1mmol/L, or fasting plasma glucose (FPG)â‰¥7.0mmol/L, or&#xD;
             plasma glucose of 2 hours post glucose-loadâ‰¥11.1 and patients diagnosed with type 2&#xD;
             diabetes; HbA1c in the range of 7%-10%;&#xD;
&#xD;
          2. Age 40-70 years;&#xD;
&#xD;
          3. Body Mass Index(BMI) 18-40;&#xD;
&#xD;
          4. Did not accepted any antihyperglycemic therapies during the past 4 weeks, or did not&#xD;
             change their antihyperglycemic treatment plan in the past 3 months;&#xD;
&#xD;
          5. Did not participate in clinical trials within three months;&#xD;
&#xD;
          6. No serious heart, brain, liver and kidney disease;&#xD;
&#xD;
          7. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Have taken any incretin drugs within recent 1 month;&#xD;
&#xD;
          2. Patients with a weakened immune system;&#xD;
&#xD;
          3. C-peptide &lt; 0.3ng/ml;&#xD;
&#xD;
          4. GLP-1 and DPP4-i drugs allergies;&#xD;
&#xD;
          5. Pregnancy and breast-feeding patients;&#xD;
&#xD;
          6. Patients taking drugs that may affect the metabolism of GLP-1 and DPP4;&#xD;
&#xD;
          7. Patients have serious heart, liver, kidney and respiratory dysfunction; Patients have&#xD;
             medullary thyroid carcinoma (MTC) with past history or family history, as well as&#xD;
             multiple endocrine neoplasia type 2 syndrome (MEN2);&#xD;
&#xD;
          8. Drug abusing and alcoholism within a year.&#xD;
&#xD;
        For non-T2D group--&#xD;
&#xD;
        No major diseases such as tumors, no dyslipidemia, chronic diseases such as hypertension,&#xD;
        and non-diabetic patients whose blood sugar and glycated hemoglobin values cannot meet the&#xD;
        criteria for diagnosis of T2DM, and the age is over 50 years old.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Enwu Long, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director of Pharmacy department</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sichuan provincial people's hospital</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Holman N, Young B, Gadsby R. Current prevalence of Type 1 and Type 2 diabetes in adults and children in the UK. Diabet Med. 2015 Sep;32(9):1119-20. doi: 10.1111/dme.12791.</citation>
    <PMID>25962518</PMID>
  </reference>
  <reference>
    <citation>Palermo A, Maggi D, Maurizi AR, Pozzilli P, Buzzetti R. Prevention of type 2 diabetes mellitus: is it feasible? Diabetes Metab Res Rev. 2014 Mar;30 Suppl 1:4-12. doi: 10.1002/dmrr.2513. Review.</citation>
    <PMID>24353270</PMID>
  </reference>
  <reference>
    <citation>Lee YS, Jun HS. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism. 2014 Jan;63(1):9-19. doi: 10.1016/j.metabol.2013.09.010. Epub 2013 Oct 17. Review.</citation>
    <PMID>24140094</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 4, 2017</study_first_submitted>
  <study_first_submitted_qc>April 5, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 11, 2017</study_first_posted>
  <results_first_submitted>June 5, 2019</results_first_submitted>
  <results_first_submitted_qc>July 14, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2020</results_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sichuan Provincial People's Hospital</investigator_affiliation>
    <investigator_full_name>Enwu Long</investigator_full_name>
    <investigator_title>Chief Pharmacist</investigator_title>
  </responsible_party>
  <keyword>DPP-4; GLP1R ; gene polymorphism research; diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sitagliptin Phosphate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT03108521/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All subjects ware recruited in medical clinic of Sichuan Provincial People's Hospital during July 26th 2016 to October 12th 2017.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Sitagliptin Group</title>
          <description>Patients in this group will accept Sitagliptin phosphate tablets as their intervention. Specifications: Each tablet 100mg (with sitagliptin dollars). Regimen: The recommended dose is 100mg.QD for 3 months.&#xD;
Sitagliptin: 100mg.QD for 3 months</description>
        </group>
        <group group_id="P2">
          <title>Non-T2D Group</title>
          <description>Aims to study correlationship between SNP and T2DM onset.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="83"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Sitagliptin Group</title>
          <description>Patients in this group will accept Sitagliptin phosphate tablets as their intervention. Specifications: Each tablet 100mg (with sitagliptin dollars). Regimen: The recommended dose is 100mg.QD for 3 months.&#xD;
Sitagliptin: 100mg.QD for 3 months</description>
        </group>
        <group group_id="B2">
          <title>Non-T2DM Group</title>
          <description>Subjects in this group are T2D free. We use their gene information to study SNP differences between T2D patients and non-T2DM people.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="83"/>
            <count group_id="B2" value="36"/>
            <count group_id="B3" value="119"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="83"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" spread="9.7"/>
                    <measurement group_id="B2" value="60.6" spread="7.26"/>
                    <measurement group_id="B3" value="57.1" spread="7.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="83"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="44"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="55"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="83"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="119"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <population>non-T2D subjects only tested HbA1c at baseline. Of the 71 patients who completed the study, 69 collected HbA1c at both baseline and study endpoint, and 2 subjects did not carry out HbA1c measurement for personal reasons.</population>
          <units>percentage of HbA1c</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="69"/>
                    <count group_id="B2" value="36"/>
                    <count group_id="B3" value="105"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.26" spread="0.88"/>
                    <measurement group_id="B2" value="5.01" spread="0.67"/>
                    <measurement group_id="B3" value="7.24" spread="1.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glycosylated Hemoglobin A1c (HbA1c)</title>
        <description>non-T2D subjects only tested HbA1c at baseline. Of the 71 patients who completed the study, 69 collected HbA1c at both baseline and study endpoint, and 2 subjects did not carry out HbA1c measurement for personal reasons.</description>
        <time_frame>12 weeks later</time_frame>
        <population>non-T2D subjects only tested HbA1c at baseline. Of the 71 patients who completed the study, 69 collected HbA1c at both baseline and study endpoint, and 2 subjects did not carry out HbA1c measurement for personal reasons.</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin Group</title>
            <description>Patients in this group will accept Sitagliptin phosphate tablets as their intervention. Specifications: Each tablet 100mg (with sitagliptin dollars). Regimen: The recommended dose is 100mg.QD for 3 months.&#xD;
Sitagliptin: 100mg.QD for 3 months</description>
          </group>
        </group_list>
        <measure>
          <title>Glycosylated Hemoglobin A1c (HbA1c)</title>
          <description>non-T2D subjects only tested HbA1c at baseline. Of the 71 patients who completed the study, 69 collected HbA1c at both baseline and study endpoint, and 2 subjects did not carry out HbA1c measurement for personal reasons.</description>
          <population>non-T2D subjects only tested HbA1c at baseline. Of the 71 patients who completed the study, 69 collected HbA1c at both baseline and study endpoint, and 2 subjects did not carry out HbA1c measurement for personal reasons.</population>
          <units>percentage of &lt;HbA1c&gt;</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.78" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Types of Gene Polymorphism</title>
        <description>24 SNPs genetic points of DPP-4, GLP-1 and GLP-1R.</description>
        <time_frame>Baseline</time_frame>
        <population>All of the participants were detected the 24 SNPs genetic points</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin Group</title>
            <description>Patients in this group will detect the 24 SNPs genetic points of DPP-4, GLP-1 and GLP-1R.</description>
          </group>
          <group group_id="O2">
            <title>Non-T2DM Group</title>
            <description>Patients in this group also will detect the 24 SNPs genetic points of DPP-4, GLP-1 and GLP-1R.</description>
          </group>
        </group_list>
        <measure>
          <title>Types of Gene Polymorphism</title>
          <description>24 SNPs genetic points of DPP-4, GLP-1 and GLP-1R.</description>
          <population>All of the participants were detected the 24 SNPs genetic points</population>
          <units>percentage of Allele frequency</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="36"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rs7565794</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.0"/>
                    <measurement group_id="O2" value="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs10166311</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5"/>
                    <measurement group_id="O2" value="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs2300757</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.2"/>
                    <measurement group_id="O2" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs2302873</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4"/>
                    <measurement group_id="O2" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs2284872</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.4"/>
                    <measurement group_id="O2" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs7608798</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.2"/>
                    <measurement group_id="O2" value="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs2111850</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.5"/>
                    <measurement group_id="O2" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs16822665</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.5"/>
                    <measurement group_id="O2" value="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Blood Glucose</title>
        <description>Fasting Blood glucose, the postprandial 0.5-hour,2-hour,3-hour blood glucose were measured at baseline and at study end points, and the difference between baseline and study end points were compared.Participants in &quot;Non-T2DM Group&quot; were not taking Sitagliptin, so their blood glucose were not measured.</description>
        <time_frame>Basline and 12 weeks later. Fasting, 0.5h, 2h,3h after take 75g glucose orally.</time_frame>
        <population>71 patients complete the study</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin Group</title>
            <description>Patients in this group will check fasting and postprandial 2-hour blood glucose</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Blood Glucose</title>
          <description>Fasting Blood glucose, the postprandial 0.5-hour,2-hour,3-hour blood glucose were measured at baseline and at study end points, and the difference between baseline and study end points were compared.Participants in &quot;Non-T2DM Group&quot; were not taking Sitagliptin, so their blood glucose were not measured.</description>
          <population>71 patients complete the study</population>
          <units>mmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Î”Fasting blood glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.60" spread="2.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Î”0.5h Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.18" spread="3.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Î”2h Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.49" spread="4.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Î”3h Glucose</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.45" spread="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Insulin</title>
        <description>Fasting insulin, the postprandial 0.5-hour,2-hour,3-hour insulin were measured at baseline and at study end points, and the difference between baseline and study end points were compared.The changes in fasting insulin, the postprandial 0.5-hour,2-hour,3-hour insulin were compared among patients with different genotypes at baseline and at study end points.Participants in &quot;Non-T2DM Group&quot; were not taking Sitagliptin, so their insulin were not measured.</description>
        <time_frame>Basline and 12 weeks later. Fasting and 0.5h, 2h,3h after take 75g glucose orally.</time_frame>
        <population>71 patients complete the study</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin Group</title>
            <description>To compare the baseline and endpoint insulin secretion after taking sitagliptin orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Insulin</title>
          <description>Fasting insulin, the postprandial 0.5-hour,2-hour,3-hour insulin were measured at baseline and at study end points, and the difference between baseline and study end points were compared.The changes in fasting insulin, the postprandial 0.5-hour,2-hour,3-hour insulin were compared among patients with different genotypes at baseline and at study end points.Participants in &quot;Non-T2DM Group&quot; were not taking Sitagliptin, so their insulin were not measured.</description>
          <population>71 patients complete the study</population>
          <units>Î¼U/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Î”Fasting insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.66" spread="4.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Î”0.5h insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.00" spread="8.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Î”2h insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.43" spread="13.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Î”3h insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.99" spread="11.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in C-peptide</title>
        <description>Fasting C-peptide, the postprandial 2-hour C-peptide were measured at baseline and at study end points, and the difference between baseline and study end points were compared.The changes in fasting C-peptide, the postprandial 2-hour C-peptide were compared among patients with different genotypes at baseline and at study end points.Participants in &quot;Non-T2DM Group&quot; were not taking Sitagliptin, so their C-peptide were not measured.</description>
        <time_frame>Basline and 12 weeks later. Fasting and 2h after take 75g glucose orally.</time_frame>
        <population>71 patients complete the study</population>
        <group_list>
          <group group_id="O1">
            <title>Sitagliptin Group</title>
            <description>Patients in this group will compare the baseline and endpoint C peptide secretion after taking sitagliptin orally</description>
          </group>
        </group_list>
        <measure>
          <title>Change in C-peptide</title>
          <description>Fasting C-peptide, the postprandial 2-hour C-peptide were measured at baseline and at study end points, and the difference between baseline and study end points were compared.The changes in fasting C-peptide, the postprandial 2-hour C-peptide were compared among patients with different genotypes at baseline and at study end points.Participants in &quot;Non-T2DM Group&quot; were not taking Sitagliptin, so their C-peptide were not measured.</description>
          <population>71 patients complete the study</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Î”Fasting C peptide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.03" spread="0.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Î”2h C peptide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" spread="1.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <desc>All-Cause Mortality, Serious, or Other (non-serious) Adverse Events were monitored/assessed, but no All-Cause Mortality or Serious Adverse Events observed during the study period.The dosage and administration of the drugs were not adjusted, and all adverse reactions improved after 3 days.</desc>
      <group_list>
        <group group_id="E1">
          <title>Sitagliptin Group</title>
          <description>Patients in this group will accept Sitagliptin phosphate tablets as their intervention. Specifications: Each tablet 100mg (with sitagliptin dollars). Regimen: The recommended dose is 100mg.QD for 3 months.&#xD;
Sitagliptin: 100mg.QD for 3 months</description>
        </group>
        <group group_id="E2">
          <title>Non-T2DM Group</title>
          <description>Subjects in this group are T2D free. We use their gene information to study SNP differences between T2D patients and non-T2DM people.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>abdominal distension and abdominal pain 8 cases, dizziness 2 cases, constipation 2 cases</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="71"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="36"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Xingwei Wu and Professor Enwu Long</name_or_title>
      <organization>Department of Pharmacy, Sichuan Academy of Medical Sciences &amp; Sichuan Provincial People's Hospital</organization>
      <phone>+8615928017367</phone>
      <email>wuxw1988@126.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

